ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Alto Neuroscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$22.82+0.88 (+4.01%)
Close on Oct 19, 2026
- Market cap
- $976.99M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$16.74 (+275.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $976.99M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.46
- Dividend yield
- –
- Free cash flow yield
- -7.05%
Fundamentals
- Net income
- -$84.24M
- EPS, diluted
- -$2.44
- Free cash flow
- -$68.84M
- Book value per share
- $5.12
- Diluted shares
- 43M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$88.27M
Net income
-$84.24M
EPS, diluted
-$2.44
Free cash flow
-$68.84M
Reported periodTrailing twelve months